Optimi Health Phase 2 Psilocybin MDD Trial
Analysis based on 15 articles · First reported Sep 10, 2026 · Last updated Sep 23, 2026
The announcement signals Optimi Health's expansion into clinical drug development, potentially strengthening its long-term positioning in the regulated psychedelic medicine sector, though near-term revenue impact is limited as the trial will not begin until 2027. The news may draw investor attention to psychedelic pharmaceutical stocks, but the lack of immediate commercialization and the company's recent stock decline suggest cautious market reaction.
Optimi Health announced plans to initiate a multisite Phase 2 clinical trial evaluating psilocybin-assisted therapy for individuals with major depressive disorder. The trial, authorized by Canada — Health Canada, will enroll up to 200 participants across multiple sites in Canada, making it one of the largest clinical studies of naturally derived psilocybin to date. The study will evaluate the safety and efficacy of a single supervised dose of natural psilocybin, with the primary efficacy endpoint being the change in Montgomery-Asberg Depression Rating Scale total score from baseline. Optimi plans to begin the trial in the first half of 2027, with dosing expected to be completed by the end of 2027. The company will supply its own naturally derived psilocybin, manufactured at its GMP-compliant facility in British Columbia, and will retain exclusive ownership of the trial results. Optimi stated it can fund the trial with current cash on hand. Major depressive disorder affects an estimated 332 million people worldwide according to the World Health Organization, and a substantial proportion of patients do not respond adequately to existing antidepressant treatments. Optimi holds a Drug Establishment Licence in Canada and supplies psilocybin through Canada — Health Canada's Special Access Program, with products also prescribed in Australia under its Authorized Prescriber Scheme. None of Optimi's psilocybin drug products have received market authorization from Canada — Health Canada.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard